MX2023002851A - Tratamiento de la enfermedad de parkinson. - Google Patents

Tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2023002851A
MX2023002851A MX2023002851A MX2023002851A MX2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A MX 2023002851 A MX2023002851 A MX 2023002851A
Authority
MX
Mexico
Prior art keywords
disease
parkinson
treatment
prasinezumab
treating
Prior art date
Application number
MX2023002851A
Other languages
English (en)
Spanish (es)
Inventor
Wagner Zago
Gennaro Pagano
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2023002851A publication Critical patent/MX2023002851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023002851A 2020-09-10 2021-09-10 Tratamiento de la enfermedad de parkinson. MX2023002851A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US202163158191P 2021-03-08 2021-03-08
PCT/US2021/049785 WO2022056209A1 (en) 2020-09-10 2021-09-10 Treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2023002851A true MX2023002851A (es) 2023-03-22

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002851A MX2023002851A (es) 2020-09-10 2021-09-10 Tratamiento de la enfermedad de parkinson.

Country Status (10)

Country Link
US (2) US12084491B2 (enExample)
EP (1) EP4211162A4 (enExample)
JP (1) JP2023541048A (enExample)
KR (1) KR20230086674A (enExample)
AU (1) AU2021338781A1 (enExample)
CR (1) CR20230121A (enExample)
IL (1) IL301039A (enExample)
MX (1) MX2023002851A (enExample)
TW (1) TW202227131A (enExample)
WO (1) WO2022056209A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20240279316A1 (en) * 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
CN117409969B (zh) * 2023-11-13 2026-04-03 深圳市臻络科技有限公司 帕金森病运动功能评估方法、装置及电子设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7981058B2 (en) 2004-03-12 2011-07-19 The Trustees Of Dartmouth College Intelligent wearable monitor systems and methods
US20060122472A1 (en) 2004-09-28 2006-06-08 Pullman Seth L System and method for clinically assessing motor function
US8702629B2 (en) 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP5251270B2 (ja) 2008-06-04 2013-07-31 三菱化学株式会社 パーキンソン病の評価装置
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US20100076348A1 (en) 2008-09-23 2010-03-25 Apdm, Inc Complete integrated system for continuous monitoring and analysis of movement disorders
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN101963919A (zh) 2009-07-24 2011-02-02 鸿富锦精密工业（深圳）有限公司 进程管理系统
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9924899B2 (en) 2013-09-09 2018-03-27 Alexis Pracar Intelligent progression monitoring, tracking, and management of parkinson's disease
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6595490B2 (ja) 2014-02-04 2019-10-23 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター 身体固定センサを使用してパーキンソン病の診断または予後を提供する方法およびシステム
US20180126158A1 (en) 2016-08-22 2018-05-10 Lyriq, Llc Systems and Methods for Functional Restoration and Rehabilitation of Posture, Gait and Movement
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
KR20230154249A (ko) 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료

Also Published As

Publication number Publication date
US12084491B2 (en) 2024-09-10
US20220098291A1 (en) 2022-03-31
WO2022056209A1 (en) 2022-03-17
TW202227131A (zh) 2022-07-16
US20250188158A1 (en) 2025-06-12
CR20230121A (es) 2023-07-26
EP4211162A4 (en) 2025-04-30
EP4211162A1 (en) 2023-07-19
JP2023541048A (ja) 2023-09-27
AU2021338781A1 (en) 2023-03-30
IL301039A (en) 2023-05-01
KR20230086674A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
CR20230121A (es) Tratamiento de la enfermedad de parkinson
CR20210508A (es) COMPUESTOS y COMPOSICIONES PARA EL TRATAMIENTO DE ENFERMEDAD
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
NI202100018A (es) Moduladores de la expresión de pnpla3
MX2021003903A (es) Terapia combinada para el melanoma.
MX2025003294A (es) Moduladores de la expresion de apol1
EA201991818A1 (ru) Лечение рака
PH12022551377A1 (en) Vegf mini-traps and method of use thereof
JOP20190190A1 (ar) معالجة سرطان
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
JOP20210216A1 (ar) علاج السرطان
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
EA202092540A1 (ru) Комбинации для лечения рака
MX2021013360A (es) Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias.
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2023129531A3 (en) Methods for diagnosing and/or treating alzheimer's disease
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
BR112021017635A2 (pt) Composições e métodos para tratar a doença de huntington
MA70825B1 (fr) Traitement de douleur associée à la sensibilisation centrale
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.